rEEcur : International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

Two/ThreePhase Two/Three

4-50Age 4-50

Sarcoma<br/>CancersCancer LocationSarcoma
Cancers

Systemic therapy | SarcomaEwing's Sarcoma,Sarcoma,Soft Tissue Sarcoma

Trial Overview Read MoreRead more

This phase II/III trial is comparing four widely used chemotherapy regimens for patients with primary refractory and recurrent Ewing Sarcoma.
 

This trial is treating patients with Ewing Sarcoma.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma

Other Non-Commercial Sponsor

Canteen - Australian Young Cancer Patient Clinical Trials Initiative

Summary

In this trial, patients will be randomised to one of four chemotherapy regimens in order to identify which treatment is the best fit for future use. All four arms are currently standard of care treatment options and will be administered as follows: (Arm 1) Topotecan and Cyclophosphamide (TC): 6 cycles of 21 days, additional cycles at clinician's discretion. IV Infusoion of Topotecan 0.75mg/m2 and Cyclophosphamide 250mg/m2 on day 1, 2, 3, 4, 5. (Arm 2) Irinotecan and Temozolomide (IT): 6 cycles of 21 days, additional cycles at clinician's discretion. IV infusion of Irinotecan 50mg/m2 on days 1, 2, 3, 4, 5 Temozolomide 100mg/m2 orally on days 1, 2, 3, 4, 5 (Arm 3) Gemcitabine and Docetaxel (GD): 6 cycles of 21 days, additional cycles at clinician's discretion. IV infusion of Gemcitabine 900mg/m2 on days 1, 8. IV infusion of Docetxal 800mg/m2 on day 8. (Arm 4) High dose Ifosfamide (IFOS): 4 cycles of 21 days. IV infusion of Ifosfamide 3g/m2 on days 1, 2, 3, 4, 5.

Recruiting Hospitals Read MoreRead more

PCCTU (Parkville Cancer Clinical Trials Unit) *
Parkville
Ms Marian Lieschke
marian.lieschke@petermac.org
03 8559 7140

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next